Treatment interruption and variation in tablet taking behaviour result in viral failure: A case-control study from cape town, south africa

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Ncaca, Lisa Noelle ^a   Kranzer, Katharina ^a,b   Orrell, Catherine ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SOUTH AFRICA; TABLET FORMULATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INTERRUPTION; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; STATISTICS; TABLET; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SOUTH AFRICA; TABLETS; TREATMENT FAILURE; VIRAL LOAD;

EID: 79961196712     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023088     Document Type: Article

References (26)

1. Parienti J, Das-Douglas M, Massari V, Guzman D, Deeks S, et al. (2008) Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One 3 (7): e2783.
2. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21-30.
3. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, et al. (2005) Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clinical Infectious Diseases 40: 158-163.
4. Bangsberg DR, (2006) Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases 42: 939-941.
5. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, et al. (2010) Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors.J Acquir Immune Defic Syndr 55 (3): e17-23.
6. Taffé P, Rickenbach M, Hirschel B, Opravil M, Furrer H, et al. (2002) Swiss HIV Cohort Study. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS 16 (5): 747-55.
7. Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, et al. (2006) Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr 15;42 (5): 554-61.
8. Oyugi j, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kamplala, Uganda. AIDS; 21: 965-971.
9. Datay MI, Boulle A, Mant D, Yudkin P, (2010) Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 54: 489-495.
10. DART Trial Team (2008) Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 counts <200 cells/μl. AIDS 22: 237-247.
11. Pogány K, Vanvalkengoed I, Prins J, Nieuwkerk P, van der Ende I, et al. (2007) Effects of active treatment discontinuation in patients with a CD4 T-cell nadir greater than 350 cells/mm3. J Acquir Immune Defic Syndr.44: 395-400.
12. Hirshel B, Flanigan T, (2009) Is it smart to continue to study treatment interruptions? AIDS 23: 757-759.
13. Holkmann-Olsen C, Mocroft A, Kirk O, Kirk O, Vella S, et al. (2007) Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Medicine; 8: 96-104.
14. d'arminio Monforte A, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, et al. (2005) Interruption of highly active antiretroviral therapy in HIV clinical practice. J Acquir Immune Defic Syndr 38: 407-416.
15. UK CHIC, (2008) Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 22: 349-356.
16. Knobel H, Urbina O, Gonzalez A, Sorli M, Montero M, et al. (2009) Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up. HIV Medicine 10: 364-369.
17. Statistics South Africa Mid-year Population Estimates (2010) Department of Health, South Africa. Available: http://www.statssa.gov.za/publications/P0302/P03022010.pdf Accessed 01 December 2010.
18. South African National Antiretroviral Treatment Guidelines (2004) National Department of Health, South Africa. Available: http://www.doh.gov.za/docs/factsheets/guidelines/artguidelines04/index.html Accessed 29 November 2010.
19. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, et al. (2007) Conservation of first line antiretroviral treatment regimen where therapeutic options are limited. Antiviral Therapy 12: 83-88.
20. Bisson GP, Rowh A, Weinstein R, Gaolathe T, Frank I, et al. (2008) Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr 49 (1): 107-10.
21. Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, et al. (2011) HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts. Infect Disord Drug Targets 11 (2): 167-74.
22. Maggiolo F, Airoldi M, Kleinloog H, Callegaro A, Ravasio V, et al. (2007) Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients. HIV Clinical Trials 8 (5): 282-292.
23. Kiguba R, Byakika-Tusiime J, Karamagi C, Hays RD, Beck CK, et al. (2007) Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans. J Acquir Immune Defic Syndr 45: 218-223.
24. Li X, Margolick JB, Conover CS, Badri S, Riddler SA, et al. (2005) Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 38 (3): 320-8.
25. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, et al. (2001) A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 134 (10): 968-77.
26. Berg KM, Arnsten JH, (2006) Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr Suppl 1: S79-87.